Skip to content
Kaylee M. Maynard

Kaylee M. Maynard

Contact

Call Center (585) 276-3000

About Me

Professional Background

Kaylee Maynard, PharmD, BCCCP earned her Doctor of Pharmacy degree from Western New England University College of Pharmacy and Health Sciences. She completed a PGY1 Pharmacy Residency and a PGY2 Critical Care Pharmacy Residency at the University of Rochester Medical Center. She practices at the Univ...
Kaylee Maynard, PharmD, BCCCP earned her Doctor of Pharmacy degree from Western New England University College of Pharmacy and Health Sciences. She completed a PGY1 Pharmacy Residency and a PGY2 Critical Care Pharmacy Residency at the University of Rochester Medical Center. She practices at the University of Rochester Medical Center in Rochester, NY as a Clinical Pharmacy Specialist in Burn/Trauma Critical Care. Her clinical practice includes working as a member of the multidisciplinary rounding team in the Kessler Family Burn/Trauma Intensive Care Unit and as the clinical pharmacist with the Burn Service.

Dr. Maynard serves as a member of the Critical Care Quality Council, Trauma Council, and the Opioid Safety Committee at UR Medicine. In addition to her clinical responsibilities, she is an active member of the American Burn Association and the Society of Critical Care Medicine. She serves as a preceptor for APPE students as well as PGY1, PGY2 Critical Care, PGY2 Emergency Medicine, and PGY2 Infectious Diseases residents.

Credentials

Post-doctoral Training & Residency

PGY2 Critical Care Pharmacy Residency at the University of Rochester Medical Center 2018 - 2019

PGY1 Pharmacy Practice Residency at the University of Rochester Medical Center 2017 - 2018

Education

Doctor of Pharmacy | Western New England University College of Pharmacy. 2017

Publications

Journal Articles

Multicenter study evaluating target attainment of anti-Factor Xa levels using various enoxaparin prophylactic dosing practices in adult trauma patients.

Chanas T, Gibson G, Langenstroer E, Herrmann DJ, Carver TW, Alexander K, Chui SHJ, Rein L, Ha M, Maynard KM, Bamberg K, O'Keefe M, O'Brien M, Gonzalez MC, Hobbs B, Pajoumand M, Peppard WJ

Pharmacotherapy.. 2023 December 26 Epub 12/26/2023.

Low-dose Initiation of Buprenorphine in Hospitalized Patients on Full Agonist Opioid Therapy: A Retrospective Observational Study.

Schult RF, Maynard KM, Corvelli JM, Rappaport S, McKinney B, Clarkson T, Wiegand TJ, Malcho J, Acquisto NM

Journal of addiction medicine.. 2023 August 18 Epub 08/18/2023.

Low-dose Initiation of Buprenorphine in Hospitalized Patients on Full Agonist Opioid Therapy: A Retrospective Observational Study.

Schult RF, Maynard KM, Corvelli JM, Rappaport S, McKinney B, Clarkson T, Wiegand TJ, Malcho J, Acquisto NM

Journal of addiction medicine.. 2023 17 (6):685-690. Epub 08/18/2023.

A review of the most impactful published pharmacotherapy-pertinent literature of 2019 and 2020 for clinicians caring for patients with thermal or inhalation injury.

Hill DM, Boyd AN, Zavala S, Adams B, Reger M, Maynard KM, Adams TR, Drabick Z, Carter K, Johnson HA, Alexander KM, Smith L, Frye J, Gayed RM, Quan AN, Walroth TA

Journal of burn care & research : official publication of the American Burn Association.. 2021 November 12 Epub 11/12/2021.

Anti-FXa Activity with Intermediate Dose Thromboprophylaxis in COVID-19.

Rappaport SH, Clark JM, Delibert S, Maynard KM, Prasad P, Kaufman DC, Pietropaoli AP, Quill CM, Groth CM

American journal of respiratory and critical care medicine.. 2020 September 15 Epub 09/15/2020.

Specialization within pharmacy education: A survey of curricular track or concentration offerings.

Parsons KA, Nemec EC, Maynard KM, Welch B

Currents in pharmacy teaching & learning.. 2018 April 10 (4):433-438. Epub 01/10/2018.